Skip to main content
. 2020 Nov 4;8(10):e2986. doi: 10.1097/GOX.0000000000002986

Table 6.

Summary of Base-case Cost-effectiveness Results across Different Study Perspectives

N Mean Costs Mean QALYs Incremental Costs Incremental QALYs ICER
Societal
 AAT 10 $14,308.00 0.74 $4574 −0.09 AAT is dominated by TE/I
 TE/I 9 $9734.00 0.83
MOH
 AAT 18 $4998.00 0.74 $2664.00 −0.09 AAT is dominated by TE/I
 TE/I 13 $2335.00 0.83

n, number of patients.